Footnotes

• Contributors MBH contributed to acquisition and analysis of data, conception and design of the study, drafting the manuscript and figures. MR contributed to acquisition and analysis of data, and critical revision of the manuscript. DD contributed to conception and design of the study, acquisition and analysis of data and study supervision.

• Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

• Competing interests DD has received research support from from the DOD (CA210208) for germ cell tumor immunoprofiling. He has consulted for UCB, Immunovant and Astellas Pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic. He has patents pending for Kelch-like protein 11 (KLHL11) IgG, Leucine Zipper 4 (LUZP4) IgG and Caveolae Associated Protein-4 (cavin-4) IgG as markers of neurological autoimmunity.

• Provenance and peer review Not commissioned; externally peer reviewed.

• Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.